IPO registrations (S-1, F-1) · Registrants
Zai Lab Ltd
- SEC CIK
- 1704292 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2017-08-15, last 2018-09-05; 2 initial registrations, 5 amendments
- Outcome
- Final prospectus filed 2017-09-21; declared effective 2017-09-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- E9
- Business address
- 899 HALEI ROAD, BUILDING B, PUDONG, Shanghai
- Ticker
- ZLAB (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Zai Lab Ltd on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per ADS (F-1/A filed 2017-09-20)
- Final price
- $18.00 per ADS, within the range (424B4 filed 2017-09-21, an initial public offering)
- Shares sold
- 8,333,333
- Gross proceeds
- $149,999,994 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ZLAB
- Lead underwriters
- J.P. Morgan; Citigroup; Leerink Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Zai Lab Ltd EXACT (CIK (EXACT))
- Person page: John D Diekman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 13
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-08-15 | F-1 | F-1 (foreign registration) | Zai Lab Ltd | 0001193125-17-258641 ↗ |
| 2017-08-23 | F-1/A | F-1/A (amendment) | Zai Lab Ltd | 0001193125-17-265550 ↗ |
| 2017-09-01 | F-1/A | F-1/A (amendment) | Zai Lab Ltd | 0001193125-17-275654 ↗ |
| 2017-09-20 | F-1/A | F-1/A (amendment) | Zai Lab Ltd | 0001193125-17-288562 ↗ |
| 2017-09-20 | F-1MEF | F-1MEF (added securities) | Zai Lab Ltd | 0001193125-17-288916 ↗ |
| 2017-09-20 | EFFECT | EFFECT (declared effective) | Zai Lab Ltd | 9999999995-17-002411 ↗ |
| 2017-09-20 | EFFECT | EFFECT (declared effective) | Zai Lab Ltd | 9999999995-17-002422 ↗ |
| 2017-09-21 | 424B4 | 424B4 (final prospectus) | Zai Lab Ltd | 0001193125-17-290496 ↗ |
| 2018-08-31 | F-1 | F-1 (foreign registration) | Zai Lab Ltd | 0001193125-18-265046 ↗ |
| 2018-09-05 | F-1/A | F-1/A (amendment) | Zai Lab Ltd | 0001193125-18-266941 ↗ |
| 2018-09-05 | F-1/A | F-1/A (amendment) | Zai Lab Ltd | 0001193125-18-267042 ↗ |
| 2018-09-05 | EFFECT | EFFECT (declared effective) | Zai Lab Ltd | 9999999995-18-002277 ↗ |
| 2018-09-07 | 424B4 | 424B4 (final prospectus) | Zai Lab Ltd | 0001193125-18-268444 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-09-20 | F-1/A | registration statement | $16.00–$18.00 | 8,000,000 | - | Nasdaq ZLAB | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2017-09-21 | 424B4 | final prospectus | $18.00 | 8,333,333 | $149,999,994 | Nasdaq ZLAB | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Chen Kai-Xian | Director | 8 | 2021–2025 | ||
| Cho William Ki Chul | Officer | Chief Financial Officer | 6 | 2021–2023 | |
| DIEKMAN JOHN D | Director | 12 | 2021–2026 | person page Fuzzy | |
| Du Ying | Director,Officer | Chairperson & CEO; Chairwoman & CEO | 58 | 2021–2026 | |
| Edmondson Frazor Titus III | Officer | Chief Legal Officer | 33 | 2021–2026 | |
| Fu Tao | Director,Officer | President & COO | 12 | 2021 | |
| Leung Nisa | Director | 4 | 2021–2026 | ||
| Liang Yi | Officer | CCO & President, Greater China | 4 | 2021–2022 | |
| Lis William | Director | 14 | 2021–2026 | ||
| MOULDER LEON O JR | Director | 7 | 2021–2026 | ||
| Reinhart Harald | Officer | Chief Medical Officer; See remarks; See Remarks | 23 | 2021–2024 | |
| Sandler Alan B. | Officer | Head of Global Dev., Oncology | 5 | 2021–2022 | |
| WIRTH PETER | Director | 12 | 2021–2026 | ||
| Qiming Corporate GP IV, Ltd | TenPercentOwner | 1 | 2021 | ||
| Qiming GP IV, L.P. | TenPercentOwner | 1 | 2021 | ||
| Qiming Managing Directors Fund IV, L.P. | TenPercentOwner | 1 | 2021 | ||
| Qiming Venture Partners IV, L.P. | TenPercentOwner | 1 | 2021 | ||
| QM 11 Ltd | TenPercentOwner | 1 | 2021 | ||
| Morrison Scott W | Director | 7 | 2021–2026 | ||
| GAYNOR RICHARD | Director | 10 | 2021–2026 | ||
| Smiley Joshua L | Officer | Chief Operating Officer; See Remarks | 19 | 2022–2026 | |
| Amado Rafael | Officer | See Remarks | 19 | 2023–2026 | |
| Vounatsos Michel | Director | 5 | 2023–2026 | ||
| Chen Yajing | Officer | Chief Financial Officer | 26 | 2023–2026 | |
| Wang Yizhe | Officer | Operating Partner | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Zai Lab Ltd | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | John D Diekman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations:
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
- Biofrontera AG 2M
- CURAXIS PHARMACEUTICAL Corp 2Q
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
Interests: Pharmaceutical Preparations · Health